HUM insider filing: Feinberg sells 441 shares, defers fees into 1,593 RSUs
Rhea-AI Filing Summary
David T. Feinberg, a director of Humana Inc. (HUM), reported changes in his beneficial ownership on a Form 4 covering transactions dated 09/30/2025. The filing shows a disposition of 441 shares of Humana common stock. It also reports holdings and movements in restricted stock units: 1,593 restricted stock units described as annual director fees deferred, an acquisition of 69 restricted stock units at a reported price of $257.7925, and 17 additional shares/units. The director elected to defer cash fees and dividend payments into stock units, which will be paid 1-for-1 in common stock upon his resignation.
Positive
- Director elected to defer cash fees and dividends into stock units, which increases alignment with shareholders
- Restricted stock units are payable 1-for-1 in common stock, preserving economic alignment over time
Negative
- Disposition of 441 shares was reported, representing an insider sale of company stock
Insights
TL;DR: Routine director compensation elections and a modest sale; neutral for Humana's capital structure.
The Form 4 indicates an ordinary director activity: conversion of cash fees and dividends into deferred restricted stock units and a separate sale of 441 shares on 09/30/2025. The reported acquisition of 69 restricted stock units at $257.7925 reflects standard director compensation mechanics rather than operational or financial shifts. Overall, these transactions are small relative to company market capitalization and do not signal a material change in insider alignment with shareholders.
TL;DR: Director is using election options to defer compensation into equity; governance signal is alignment rather than divestiture.
The filing explicitly notes that annual director fees, elected cash fees, and reinvested dividends were deferred into stock units payable 1-for-1 in common stock upon resignation. Such elections are common governance practices to align director incentives with shareholder outcomes. The separate reported disposition of 441 shares is disclosed as required but is not presented as linked to any change in director role or company policy.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 69 | $257.7925 | $18K |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Humana Common | -- | -- | -- |
Footnotes (1)
- Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person. Stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election. Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan. Per the Director's election, deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).
FAQ
What transactions did the HUM Form 4 report for David T. Feinberg?
When did the reported transactions for HUM occur?
Why were restricted stock units issued to the director in the HUM filing?
What price is noted for the acquired restricted stock units in the HUM Form 4?
Does the Form 4 indicate any change in the reporting person's role at HUM?